H.R.3379 - Price Relief, Innovation, and Competition for Essential Drugs Act116th Congress (2019-2020) |
|Sponsor:||Rep. Schakowsky, Janice D. [D-IL-9] (Introduced 06/20/2019)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 06/21/2019 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Summary: H.R.3379 — 116th Congress (2019-2020)All Information (Except Text)
Introduced in House (06/20/2019)
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.